Welcome to the Population Approach Group in Europe

Tuesday

14:00-17:00	Registration at the Conference Venue


19:00-22:00	Opening Ceremony, Welcome Reception


Wednesday

8:00-8:40	Registration at the Conference


8:40-8:45	Welcome by the local organizer		Carlos Garay

8:45-9:00	Welcome and Introduction		Oscar Della Pasqua and Thomas Dorlo

9:00-10:20	Generative AI & Machine Learning in Model Building		Paolo Magni & Thomas Dumortier

9:00-9:20	Lorenzo Contento	Improving simulations by learning the true random effects' distribution from a population using generative machine learning

9:20-9:40	Sam Richardson	Automating Population Pharmacokinetic Model Development using Machine Learning

9:40-10:00	Gilbert Koch	Learning from machine learning - how to deduce a mechanism-based pharmacometrics model for serum creatinine in preterm neonates from neural ordinary differential equations

10:00-10:20	Ercan Suekuer	PMx-AI Bot: Changing the way of traditional Pharmacometrics work with AI Bots

10:20-11:50	Coffee Break, Poster and Software session I


11:50-12:30	Tutorial		Martin Bergstrand

11:50-12:30	Paolo Denti	Handling within-subject/between-occasion variability in longitudinal data: Common Challenges and Practical Solutions

12:30-14:00	Lunch


14:00-15:20	Integrating Real-World Data & Pharmacometrics		Pascal Girard & Oscar Della Pasqua

14:00-14:20	Pascal Chanu	A disease model for Multiple Myeloma developed using Real World Data and validated on Phase 3 clinical trials

14:20-14:40	Samer Mouksassi	Streamlining Clinical Development of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Pediatric Chronic Kidney Disease Patients by Integration of Clinical Trial and Real-World Data

14:40-15:00	Luca Marzano	Overcoming the discrepancies between clinical trials and real-world data of small cell lung cancer chemotherapy. A data-driven approach to learn across real-world evidence studies

15:00-15:20	Aole Zheng	A Novel Approach Using Pharmacometrics/Pharmacoeconomic (PMPE) Model for Cost-effectiveness Analysis of Tacrolimus-Diltiazem Combination in Liver Transplant Patients: Evidence from Real-world Clinical Data

15:20-16:50	Coffee Break, Poster and Software session II


16:50-17:30	Improving Clinical Trials for Rare Diseases		Monica Simeoni

16:50-17:10	Alzahra Hamdan	Integrated modeling of digital-motor outcomes and clinical outcome assessments using IRT: a framework for developing better outcomes for clinical trials in rare neurological diseases

17:10-17:30	Marina Savelieva	Virtual Patient Cohorts using Modeling and Simulation to support drug development in rare diseases

Thursday

8:30-9:45	Lewis Sheiner Student Session		Siv J�nsson, J�r�mie Guedj, Coen van Hasselt

8:30-8:55	Wendy Chu	Optimizing dosing strategies for post-kala-azar dermal leishmaniasis: a geographical comparison of systemic and skin pharmacokinetics and pharmacodynamics of antileishmanial drugs

8:55-9:20	Selma El Messaoudi	Mechanistic modeling of the long-term dynamics of viral markers to predict the outcome of combination therapy in chronic HBV and HDV infections

9:20-9:45	Julie Dudasova	Logistic regression-based approach to assess heterogeneity in vaccine efficacy using immunogenicity measurements in phase 3 clinical trials

9:45-9:50	Presentation Lewis Sheiner Student Session Awards


9:50-11:20	Cofee break, Poster and Software session III


11:20-12:40	Dose extrapolation & posology		Stefanie Hennig & Thomas Dorlo

11:20-11:40	Rik Schoemaker	Quantification of the analgesic effect of intranasal coadministration of ketamine and sufentanil in adults to support the development of a pain relief treatment (CT001) in children

11:40-12:00	Sandrine Boulet	Bayesian framework for multi-source data integration - application to Human extrapolation from preclinical studies

12:00-12:20	Laila Nassar	Pharmacokinetics During Hemodialysis and Hemodiafiltration: Dialysis Clearance is more important than Dialysis Efficiency - Application to Amikacin

12:20-12:40	Davide Bindellini	From physiology to disease: A quantitative framework for system-disease-drug interaction in cortisol replacement therapy

12:40-14:10	Lunch


14:10-14:50	Protein Drugs & Degraders		Roc�o Lled�-Garc�a

14:10-14:30	Javier Sanchez Fernandez	Optimizing Molecule Design for Bispecific Antibodies in Immuno-Oncology: A Case Study with FAP-4-1BBL

14:30-14:50	Robin Haid	Transforming the discovery of targeted protein degraders: the translational power of predictive PK/PD modeling

14:50-15:00	ISoP Update		Vijay Ivaturi

15:00-16:30	Coffee Break, Poster and Software session IV


16:30-17:30	Stuart Beal Methodology Session		Gilbert Koch & Marylore Chenel

16:30-16:50	Auriane Gabaut	High-dimension Mechanistic Model Building using LASSO Approaches : Application to Ebola Vaccination

16:50-17:10	Nelleke Snelder	Time-varying covariates, mediation analysis and overadjustment bias in PK/PD modelling

17:10-17:30	Mohamed Tarek	Make models great again by optimally restricting parameters to make non-identifiable models provably identifiable

20:00-01:00	Gala Dinner


Friday

9:15-10:15	Vaccines & Antibiotics		France Mentr� & Zinnia Parra Guill�n

9:15-9:35	Lorenzo Dasti	A Quantitative System Pharmacology model for the development and optimization of mRNA vaccines.

9:35-9:55	Erwin Dreesen	A patient stratification tool for selecting tuberculosis treatment regimen composition and duration

9:55-10:15	Carlos Olivares	Mathematical Modeling Of Gut Microbiota Diversity Under The Effects of Beta-lactam Antibiotics

10:15-10:20	Preview of PAGE 2025


10:20-11:05	Coffee Break


11:05-11:45	Oncology		Ana Ruiz

11:05-11:25	Ruben Taieb	Mechanistic modelling of tumor kinetics coupled with biomarker dynamics for survival prediction in non-small cell lung cancer patients

11:25-11:45	Elisabeth Rouits	Incorporating clinical utility and Pharmacokinetics (PK)/Pharmacodynamics (PD) in clinical development of oncology drug candidate with a Bayesian decision analysis perspective in the context of OPTIMUS initiative

11:45-11:55	Closing Remarks